-
Recent reporting relied on incomplete releases
We all know that press releases are, by definition, designed to highlight positive news. And that’s being generous. But a pair of…
-
First Amendment defense fails InterMune exec
If any company thinks a press release is protected speech under the First Amendment of the U.S. Constitution and, therefore, can’t be used…
-
Pharma industry still finding its way in social media
Big pharma continues to dabble, tentatively, with social media. The latest example is GlaxoSmithKline, which this week launched its very own…
-
European ruling equates journalism, advertising
Can information about medicines that is communicated by third parties – such as journalists – constitute advertising? How about when the…
-
Panel: Is media to blame for pharma’s poor image?
Several months ago, Ray Kerins, a top Pfizer public relations exec, bemoaned the perception of the pharmaceutical industry in a…
-
Panel to explore media’s ‘wanton witch hunt’
Is there a wanton witch hunt against academic experts by the media? That’s what a panel will explore this coming November…
-
CSPI shuts down Integrity in Science Watch
The ongoing economic crunch has claimed yet another casualty – the Integrity in Science Watch program that was run by…
-
Nature survey: Scientists gain influence with blogs
As newspapers shrink, fold or migrate entirely to the Internet, what will happen to science journalism? Like other topics, coverage…
-
Survey finds barriers to shared decision making
Do doctors really want their patients involved in decision making? And even if many do, what are the barriers that…
-
FDA leader warns staff about leaking information
One day, President Barack Obama is calling for open government and transparency. The next, the acting FDA commissioner, Frank Torti,…